Comments
Loading...

Inhibikase Therapeutics

IKTNASDAQ
Logo brought to you by Benzinga Data
$1.95
-0.03-1.52%
After Hours: 9:05 AM EDT
Q3 2024 Earnings were released on Thu Nov 14th, before the market open

Inhibikase Therapeutics (NASDAQ:IKT) Stock Quotes, Forecast and News Summary

Inhibikase Therapeutics Stock (NASDAQ: IKT) stock price, news, charts, stock research, profile.

Open$1.98
Close-
Volume / Avg.256.23K / 474.19K
Day Range$1.75 - $2.03
52 Wk Range0.80 - 3.82
Market Cap$135.06M
P/E Ratio-
Dividend Yield-
ExchangeNASDAQ
RSI
41
Short Interest
0.35%
Days to Cover1

Financials

Quarterly
Annual
Name
Revenue
Change
Gross
Change
EBITDA
Change
EBIT
Change
Earnings
Change
Analyst Trends and Forecast
1
Aug
1
Oct
1
Nov
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
4.0
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell
Open$1.98
Close-
Volume / Avg.256.23K / 474.19K
Day Range$1.75 - $2.03
52 Wk Range0.80 - 3.82
Market Cap$135.06M
P/E Ratio-
Dividend Yield-
ExchangeNASDAQ
RSI
41
Short Interest
0.35%
Days to Cover1

Compare

EPS worse than industry
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.
IKT
OTLK

FAQ

Q

How do I buy Inhibikase Therapeutics (IKT) stock?

A

You can purchase shares of Inhibikase Therapeutics (NASDAQ:IKT) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Inhibikase Therapeutics (IKT) competitors?

Q

What is the forecast, or price target, for Inhibikase Therapeutics (IKT) stock?

A

Inhibikase Therapeutics has a consensus price target of $6.50.

Q

What is the current price for Inhibikase Therapeutics (IKT)?

A

The stock price for Inhibikase Therapeutics (NASDAQ: IKT) is $2.01 last updated November 21, 2024 at 4:00 PM EST.

Q

Does Inhibikase Therapeutics (IKT) pay a dividend?

A

There are no upcoming dividends for Inhibikase Therapeutics.

Q

When is Inhibikase Therapeutics (NASDAQ:IKT) reporting earnings?

A

Inhibikase Therapeutics’s Q3 earnings are confirmed for Thursday, November 14, 2024.

Q

Is Inhibikase Therapeutics (IKT) going to split?

A

There is no upcoming split for Inhibikase Therapeutics.

Q

What sector and industry does Inhibikase Therapeutics (IKT) operate in?

A

Inhibikase Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

People Also Watch